Profund Advisors LLC Has $299,000 Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Profund Advisors LLC grew its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 68.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,194 shares of the specialty pharmaceutical company’s stock after buying an additional 4,543 shares during the quarter. Profund Advisors LLC’s holdings in Supernus Pharmaceuticals were worth $299,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in SUPN. Sei Investments Co. boosted its stake in Supernus Pharmaceuticals by 2.1% during the 2nd quarter. Sei Investments Co. now owns 337,658 shares of the specialty pharmaceutical company’s stock valued at $9,032,000 after purchasing an additional 7,078 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of Supernus Pharmaceuticals by 100,186.3% during the second quarter. Pacer Advisors Inc. now owns 1,349,854 shares of the specialty pharmaceutical company’s stock valued at $36,109,000 after buying an additional 1,348,508 shares during the last quarter. Intech Investment Management LLC bought a new stake in Supernus Pharmaceuticals during the second quarter worth $303,000. XTX Topco Ltd purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $419,000. Finally, Edgestream Partners L.P. bought a new position in Supernus Pharmaceuticals during the 2nd quarter valued at $2,029,000.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $30.75 on Friday. The company has a market capitalization of $1.69 billion, a PE ratio of -106.03 and a beta of 0.88. Supernus Pharmaceuticals, Inc. has a 1 year low of $21.99 and a 1 year high of $35.44. The business has a fifty day moving average price of $32.27 and a two-hundred day moving average price of $30.43.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). The company had revenue of $168.30 million for the quarter, compared to analysts’ expectations of $148.83 million. Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The business’s quarterly revenue was up 24.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.02) EPS. Sell-side analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current year.

Analysts Set New Price Targets

SUPN has been the subject of several analyst reports. Piper Sandler downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $41.00 to $36.00 in a report on Wednesday, September 11th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.